User menu

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial

Bibliographic reference Cardozo, Linda ; Hessdörfer, Elke ; Milani, Rodolfo ; Arano, Pedro ; Dewilde, Luc ; et. al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. In: BJU international, Vol. 102, no. 9, p. 1120-7 (2008)
Permanent URL http://hdl.handle.net/2078.1/120411
  1. Irwin, Eur Urol, 50, 1306 (2006)
  2. Milsom, BJU Int, 87, 760 (2001)
  3. Stewart, World J Urol, 20, 327 (2003)
  4. Abrams, Neurourol Urodyn, 21, 167 (2002)
  5. Abrams, Neurourol Urodyn, 25, 293 (2006)
  6. Chapple, BJU Int, 95, 335 (2005)
  7. Payne, BJU Int, 99, 101 (2007)
  8. Chapple, Int J Clin Pract, 60, 959 (2006)
  9. Chapple C.R., Martinez-Garcia R., Selvaggi L., Toozs-Hobson P., Warnack W., Drogendijk T., Wright D.M., Bolodeoku J., A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial, 10.1016/j.eururo.2005.05.015
  10. Michel, BJU Int, 96, 37 (2005)
  11. Committee for Proprietary Medicinal Products., Note for Guidance on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence. CPMP/EWP/18/01. (2002)
  12. Michel, Urology, 68, 71 (2008)
  13. Artibani, Eur Urol Suppl, 6, 17 (2007)
  14. Schagen van Leeuwen, Eur Urol, 50, 440 (2006)